42例伏立康唑治疗肺真菌感染患者的不良反应  

Adverse Reactions of Voriconazole in 42 Patients with Pulmonary Mycoses

作　　者：蔡然[1] 张杰根[2] 刘晓蒙[1] 戴富林[2] 

机构地区：[1]河北省涿州市医院药剂科,河北涿州072750 [2]河北省涿州市医院呼吸内科,河北涿州072750

出　　处：《临床药物治疗杂志》2013年第2期48-51,共4页Clinical Medication Journal

基　　金：保定市科学技术研究与发展指导计划(12ZF040)

摘　　要：目的:评价伏立康唑治疗肺真菌感染的不良反应。方法:2012年3月至2012年12月,临床药师在呼吸科病房对应用伏立康唑的患者给予药学监护,重点监测不良反应。对应用伏立康唑前后进行相关的实验室检查,采用Naranjo法评定药物与不良反应因果关系。对患者的用药情况,不良反应发生时间、临床表现、持续时间、处理方法、临床转归等进行描述与评价。结果:42例患者中15例发生伏立康唑相关不良反应,不良反应发生率为35.7%。由于相互作用导致严重不良反应2例。结论:伏立康唑易发生药物相互作用,不良反应较多,应密切监测不良反应,谨慎合并用药。Objective： To evaluate the adverse reactions of voriconazole for pulmonary mycoses. Methods： From March 2012 to December 2012,the clinical pharmacist took pharmaceutical care for patients who received voriconazole and focused on the monitoring of adverse reactions in respiratory department. Related laboratory tests were conducted before and after the administration of voriconazole, and the evaluation of causality between drugs and adverse reactions were performed using the Naranjo.We described and evaluated the situation of drug use,and occurrence time,clinical manifestations, duration, treatment methods,and clinical outcome of the adverse reactions.Results： 15 of 42 patients had adverse reactions related to voriconazole,the incidence of adverse reactions was 35.7%.Among them,2 cases developed serious adverse reactions due to the drug interactions. Conclusion： Voriconazole has multiple adverse reactions and prones to developing drug interactions,so close monitoring of adverse reactions and cautious drug combinations are required in the clinical.

关 键 词：伏立康唑 肺真菌病 不良反应 临床药师 

分 类 号：R978.5[医药卫生—药品] R969.3[医药卫生—药学]